MicroRNA-338-5p alleviates neuronal apoptosis via directly targeting BCL2L11 in APP/PS1 mice

Junhua Li1,2,3, Danhua Li4,2, Huatao Zhou5,2

  • 1Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.

Aging
|October 22, 2020
PubMed

Insights

MicroRNA-338-5p levels decrease in Alzheimer's disease models. Overexpressing this microRNA (miRNA) protects against amyloid plaques and cognitive decline, suggesting a therapeutic role.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are key regulators in Alzheimer's disease (AD) pathogenesis.
  • MiR-338-5p influences neuronal differentiation and neurogenesis but its role in AD is unclear.
  • Aberrant miR-338-5p expression is observed in patients with cognitive dysfunction.

Purpose of the Study:

  • To investigate the role and mechanism of miR-338-5p in Alzheimer's disease.
  • To determine if miR-338-5p has a protective effect in AD models.

Main Methods:

  • Assessed miR-338-5p expression in APP/PS1 mice.
  • Overexpressed miR-338-5p using lentiviral vectors in the hippocampus of APP/PS1 mice.
  • Evaluated amyloid-beta (Aβ) plaque deposition, cognitive function, and neuronal apoptosis.
  • Investigated the regulatory effect of miR-338-5p on BCL2L11 in vitro.

Main Results:

  • miR-338-5p expression was reduced in APP/PS1 mice, inversely correlating with Aβ levels.
  • miR-338-5p overexpression reduced Aβ plaque deposition and improved cognitive deficits in APP/PS1 mice.
  • miR-338-5p inhibited neuronal apoptosis in vivo and in vitro by downregulating BCL2L11.

Conclusions:

  • miR-338-5p acts as a protective factor against Alzheimer's disease progression.
  • The neuroprotective effect of miR-338-5p is mediated through the inhibition of neuronal apoptosis via BCL2L11 regulation.
  • miR-338-5p represents a potential novel therapeutic target for Alzheimer's disease.